Clinical trial

A Single Centre Randomized Control Trial of Donor Site Wound Dressing After Split Thickness Skin Grafting

Name

Approval/2022/943

Description

The goal of this clinical trial\] is to compare different types of dressings used and there outcomes on STSG donor site wound. The main question\[s\] it aims to answer are: * the effectiveness of different donor site dressings and their adverse outcomes * the satisfaction of patients with the donor site dressing will be observed. Participants will randomly allocated different types of dressings for split thickness skin graft donor site wound which include alginate hydrocolloid hydrofiber silicon film guaze

Trial arms

Trial start

2022-08-01

Estimated PCD

2023-02-28

Trial end

2023-02-28

Status

Completed

Phase

Early phase I

Treatment

different types of dressings

different types of dressings were compared ti see the effectiveness for for STSG donor site wound

Arms:

alginate, film, guaze, hydrocolloid, hydrofiber, silicon

Size

Primary endpoint

to asses the effective of dressings by measuring itching , pain and scarring

six month

Eligibility criteria

Inclusion Criteria: * . Patients of aged 18 years and above of either gender underwent single donor-site wounds after split-skin grafting and surface area larger than 10 cm2 were included in the study Exclusion Criteria: * Patients on chemotherapy or corticosteroids were excluded from the study. Non-probability consecutive sampling was employed

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'SCREENING', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 90, 'type': 'ACTUAL'}}

Updated at

2023-09-21

1 organization

1 product

2 indications

Organization

Dow University of Health Sciences

Product

Dressings

Indication

Donor Site Complication

Indication

Scar